Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia

American Heart Journal

Volumn 149, Issue 1, 2005, Pages e1-

  Jones, Peter H ^a   McKenney, James M ^b   Karalis, Dean G ^c   Downey, Jackson ^d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b National Clinical Research Inc   (United States)

^c Cardiology Consultants of Philadelphia   (United States)

^d Jacksonville Center for Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ASTHENIA; BACKACHE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSPEPSIA; FEMALE; FLU LIKE SYNDROME; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MYALGIA; NAUSEA; NUTRITIONAL DISORDER; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN;

EID: 12344300436     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.07.025     Document Type: Article

References (16)

1. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final Report. NIH Publication No. 02-5215. September 2002.
2. Pfizer Inc. Lipitor United States product insert Available at: www.pfizer.com/hml/pi's/lipitorpi.pdf [Accessed September 16, 2003]
3. H. Schrott, A.G. Fereshetian, and R.H. Knopp A multicenter, placebo-controlled, dose-ranging study of atorvastatin J. Cardiovasc. Pharmacol. Ther. 3 1998 119 124
4. D.O. Fedder, C.E. Koro, and G.J. L'Italien New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population Circulation 105 2002 152 156
5. T.A. Pearson, I. Laurora, and H. Chu The Lipid Treatment Assessment Project (L-TAP). A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals Arch. Intern. Med. 160 2000 459 467
6. EUROASPIRE Study Group EUROASPIRE. A European society of cardiology survey of secondary prevention of coronary disease: principal results Eur. Heart J. 18 1997 1569 1582
7. EUROASPIRE Group Coronary prevention guidelines-the clinical reality. A comparison of EUROSPIRE I and II surveys in 9 countries Lancet 357 2001 995 1001
8. J.J. Marcelino, and K.R. Feingold Inadequate treatment with HMG-CoA reductase inhibitors by health care providers Am. J. Med. 100 1996 605 610
9. D. Monkman Treating dyslipidaemia in primary care BMJ 321 2000 1299 1300
10. M.J. Koren, D.G. Smith, and D.B. Hunninghake The cost of reaching National Cholesterol Education Panel (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin Pharmacoeconomics 14 1998 59 70
11. A.S. Brown, R.G. Bakker-Arkema, and Y. Yellen Treating patients with documented atherosclerosis to NCEP-recommended LDL cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin J. Am. Coll. Cardiol. 32 1998 665 672
12. C.B. Newman, G. Palmer, and H. Silbershatz Safety of atorvastatin derived from analysis of 44 completed trials in 9416 patients Am. J. Cardiol. 92 2003 670 676
13. T.C. Andrews, C.M. Ballantyne, and J.A. Hsia Achieving and maintaining National Cholesterol Program low-density lipoprotein cholesterol goals with five statins Am. J. Med. 111 2001 185 191
14. B. Pitt, D. Waters, and W.V. Brown Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease N. Engl. J. Med. 341 1999 70 76
15. G.G. Schwartz, A.G. Olsson, and M.D. Ezekowitz Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes JAMA 285 2001 1711 1718
16. C.P. Cannon, E. Braunwald, and C.H. McCabe Intensive versus moderate lipid lowering with statins after acute coronary syndromes N. Engl. J. Med. 350 2004 1495 1504